Navigation Links
FDA Issues Safety Alert on Avandia

ROCKVILLE, Md., May 21, 2007-The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials of Avandia, including an interim analysis of data from the RECORD trial (a large, ongoing, randomized open label trial) and unpublished reanalyses of data from DREAM (a previously conducted placebo-controlled, randomized trial) provide contradictory evidence about the risks in patients treated with Avandia.

Patients who are taking Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack should talk to their doctor about this new information as they evaluate the available treatment options for their type 2 diabetes.

FDA's analyses of all available data are ongoing. FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies. Pending questions include whether the other approved treatment from the same class of drugs, pioglitazone, has less, the same or greater risks. Furthermore, there is inherent risk associated with switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments. For these reasons, FDA is not asking GlaxoSmithKline, the drug's sponsor, to take any specific action at this time. FDA is providing this emerging information to prescribers so that they, and their patients, can make individualized treatment decisions.

"FDA remains committed to assuring that doctors and patients have the latest information available to make treatment and medication use decisions. In th
'"/>




Page: 1 2 3

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Managing Preanalytical Processes for Patient Safety
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
9. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
10. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
11. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Issues Safety Alert Avandia
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
(Date:11/24/2014)... , Nov. 24, 2014 Luoxis Diagnostics, ... MKT: AMPE), today announced the presentation of three ... System as a broadly applicable and robust research ... the body in response to injury, illness, or ... in collaboration with Luoxis, academic and pharmaceutical research ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... 20, 2011 Robbins & Myers, Inc. (NYSE: ... first quarter fiscal 2012 ending November 30, 2011 before the ... 9:00 a.m., CT / 10:00 a.m., ET on January 6.  ... J. Brown, Interim Chief Financial Officer & Corporate Controller, will ...
... HACKENSACK, N.J., Dec. 20, 2011 In an ... error rates, HackensackUMC recently announced the implementation of ... SurgiCount Safety-Sponge®  is a product of SurgiCount Medical, ... Technologies, Inc. (OTCBB:PSTX, OTCQB:PSTX). This system provides a ...
Cached Medicine Technology:HackensackUMC Adopts SurgiCount Safety-Sponge® System 2HackensackUMC Adopts SurgiCount Safety-Sponge® System 3
(Date:11/26/2014)... Obispo, CA (PRWEB) November 26, 2014 ... is offering lower prices in an early celebration of ... Bunion Booties are being offered at the promotional price ... promotional pricing is in addition to any automatic discounts ... the Bunion Bootie website for complete details. ...
(Date:11/26/2014)... Rouge, Louisiana (PRWEB) November 26, 2014 ... neck pain relief and specialists in minimally invasive ... K. Samer Shamieh into the rapidly growing provider ... specialists. The addition coincides with the network’s ... reliable medical treatment for Louisiana residents who are ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer ... Preceptorship Award from The American Association of ... advancement of nurse practitioners. The Distinguished Preceptorship Award ... made a significant contribution toward increasing the awareness ... Nurse Practitioners (AANP) is the largest full-service national ...
(Date:11/26/2014)... -- Youngsters who enter puberty early are at increased ... puberty was linked with a number of factors associated ... levels, according to the researchers. Early puberty was also ... and peers, and having friends who were prone to ... study found an association between early puberty and these ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Teens prescribed ... to abuse those drugs than other teens, a ... need to conduct substance abuse assessments on teenagers ... said. "Prescribers and parents don,t realize the ... professor at the University of Michigan School of ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... Doctors more often tell younger people to change diet, get ... -- Americans over 60 with high blood pressure are less ... on how lifestyle changes can lower their blood pressure, a ... North Carolina at Chapel Hill analyzed data from a U.S. ...
... Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical",or ... high-quality,pharmaceutical grade glucose products in China, today reported ... 2007. First Quarter of Fiscal 2008 Highlights ... $19.4 million -- Gross profit rose ...
... PORTLAND, Ore., Nov. 15 Every year more,holiday ... will stand,out above the rest while helping families ... organization, has taken this,charitable holiday gift-giving approach to ... http://www.mercycorps.org . Mercy Kits give people ...
... Va., Nov. 15 With the holidays,quickly approaching, ... As decorations go up, extension cords will be ... The Electrical Safety Foundation,International (ESFI) urges you to ... improper use can pose serious shock and fire ...
... Approved for Retreating Both Hepatitis ... C Relapsers and Nonresponders, ... today announced that the European Commission on,October 30 approved 48-week ... (ribavirin, 800 - 1,400 mg,daily) combination therapy for retreating adult ...
... life is one key factor to avoiding a number of ... University of Arizona and the University of Wisconsin, Madison, indicates ... have a strong relationship are more likely to delay the ... in the Norton School of Family and Consumer Sciences at ...
Cached Medicine News:Health News:Older Hypertension Patients Less Likely to Get Lifestyle Advice 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 11Health News:Online Charitable Holiday Giving: Making a Difference with the Gifts You Give 2Health News:Holiday Decorating and Extension Cords 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Girls will be girls longer when home life is stable 2
... The VASER System represents a ... ultrasonic technology to cosmetic procedures. Combined ... selective tissue emulsification, a solid grooved ... the VASER System has been designed ...
... The next generation of the ... PSI-TEC III retains all the ... PSI-TEC a leading name for,aspiration ... flow,vacuum pumps for high powered ...
Richardson Retractor...
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
Medicine Products: